DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Humira (Adalimumab) - Published Studies

 
 



Humira Related Published Studies

Well-designed clinical trials related to Humira (Adalimumab)

Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. [2014]

Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis. [2014]

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). [2014]

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. [2013]

Serum adalimumab concentration and clinical remission in patients with Crohn's disease. [2013]

Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. [2012]

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. [2012]

Abatacept for Crohn's disease and ulcerative colitis. [2012]

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. [2012]

Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. [2012]

Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]

Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis. [2011.11.03]

Adalimumab (anti-TNF-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. [2011.10.20]

Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. [2011.10]

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. [2011.09]

311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. [2011.08]

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. [2011.08]

Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. [2011.07]

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. [2011.06]

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. [2011.05.24]

IBD: Adalimumab for ulcerative colitis- is the glass half empty or half full? [2011.05]

Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. [2011.05]

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. [2011.04]

Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. [2011.02.27]

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. [2011.02.01]

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2011.02]

Adalimumab in ulcerative colitis: hypes and hopes. [2011.01]

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. [2011.01]

Update on the management of inflammatory bowel disease: specific role of adalimumab. [2011]

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. [2011]

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2010.12.07]

Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. [2010.11]

Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. [2010.09.03]

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. [2010.09]

Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. [2010.08]

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. [2010.08]

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. [2010.06]

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics. [2010.05.10]

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. [2010.05]

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. [2010.04]

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. [2010.04]

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. [2010.02]

Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. [2010.02]

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. [2010.01]

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. [2010]

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. [2010]

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. [2010]

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. [2009.11]

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. [2009.11]

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. [2009.08]

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. [2009.07]

Adalimumab for the treatment of fistulas in patients with Crohn's disease. [2009.07]

Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. [2009.07]

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. [2009.06]

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. [2009.05]

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). [2009.05]

Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. [2009.04]

Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. [2009.04]

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. [2009]

Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. [2008.12.09]

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. [2008.12]

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. [2008.11]

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. [2008.10.15]

Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. [2008.10.15]

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. [2008.10.02]

Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. [2008.10]

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. [2008.09]

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. [2008.08.21]

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. [2008.07]

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). [2008.07]

Adalimumab Reduces Pain, Fatigue, and Stiffness in Patients with Ankylosing Spondylitis: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS). [2008.05.15]

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. [2008.03]

Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. [2008.02]

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. [2008.01]

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. [2008]

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. [2007.11.28]

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]

Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. [2007.11]

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. [2007.10.11]

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. [2007.09]

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. [2007.08.15]

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. [2007.07.30]

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. [2007.06.19]

Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. A Randomized Trial. [2007.04.30]

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. [2007.02]

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. [2007]

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. [2006.10]

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. [2006.07]

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. [2006.06]

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. [2006.02]

Safety Analyses of Adalimumab (HUMIRA(R)) in Global Clinical Trials and US Postmarketing Surveillance of Patients With Rheumatoid Arthritis. [2006.01.26]

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. [2006.01]

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. [2005.10]

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. [2005]

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. [2004.06]

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. [2004.05]

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. [2004.05]

Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. [2004]

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). [2003.12]

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. [2003.12]

Role of adalimumab in the treatment of early rheumatoid arthritis. [2003.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014